Loading...
ENDP.Q logo

Endo, Inc.OTCPK:ENDP.Q Rapporto sulle azioni

Cap. di mercato US$141.1k
Prezzo delle azioni
n/a
US$16.66
n/dsconto intrinseco
1Y-98.9%
7D0%
1D
Valore del portafoglio
​
Vista

Endo, Inc.

Report azionario OTCPK:ENDP.Q

Capitalizzazione di mercato: US$141.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International (ENDP.Q) Panoramica del titolo

A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. Maggiori dettagli

ENDP.Q analisi fondamentale
Punteggio fiocco di neve
Valutazione4/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria2/6
Dividendi0/6

Premi

Negoziato a 100% al di sotto della nostra stima del suo valore equo

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi rispetto al mercato US

Patrimonio netto negativo

Gli utili sono diminuiti del 41.7% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( $141K )


ENDP.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Endo International plc

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Endo International
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.0006
Massimo di 52 settimaneUS$0.08
Minimo di 52 settimaneUS$0.000001
Beta0.80
Variazione di 1 mese50.00%
Variazione a 3 mesi0%
Variazione di 1 anno-98.91%
Variazione a 3 anni-99.99%
Variazione a 5 anni-99.99%
Variazione dall'IPO-100.00%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Aug 16

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Endo International (NASDAQ:ENDP) creditors are looking at putting the pharma company up for sale through a bankruptcy, likely through a Chapter 11 filing in New York, Bloomberg reported. Endo (ENDP) has a debt load of more than $8B and is still facing many lawsuits over its alleged role in the nation's opioid epidemic. A bankruptcy filing would make it easier for Endo (ENDP) to make deals with with governments and other entities suing the company. Bloomberg said that some first-lien lenders are competing to use their debt holdings toward a bid for the company’s assets. Seeking Alpha contributor CashFlow Hunter, which has a strong sell rating on Endo (ENDP), has said a bankruptcy filing is imminent.
Seeking Alpha • Aug 03

Endo International sees 23% rise on 3x higher than normal volume

Shares of Endo International (NASDAQ:ENDP) have risen sharply and are up 23% Wednesday afternoon amid three times higher than usual daily volume. The drugmaker's average daily volume is ~46.2M shares. As of 215p ET, more than 138M shares had traded hands. Endo (ENDP) is also having unusual options trading volume that is six times the daily normal. Seeking Alpha contributor CashFlow Hunter says the company is a strong sell with a bankruptcy filing likely.
Seeking Alpha • Jul 25

Endo outperforms defying bankruptcy fears and generic entry

The shares of Endo International (NASDAQ:ENDP) rose sharply on Monday even as the company continues to grapple with concerns over the generic threat to a key drug, failure to fulfill debt commitments, and potential bankruptcy filing amid ongoing opioid litigation. Despite an ~89% YTD decline, Endo (ENDP) has added ~13% over the past 30 days outperforming the broader market, as shown in this graph. The upsurge comes despite a recent WSJ report on the company’s plan to file for Chapter 11 bankruptcy without striking a settlement on thousands of opioid claims. In June, Dublin, Ireland-based Endo (ENDP) opted to skip interest payments owed to its junior bondholders citing the ongoing talks with certain creditors regarding its decision to evaluate strategic alternatives. A decline in earnings, driven in part by the loss of exclusivity for its leading sales generator, Vasostrict, has exacerbated the operational issues. In May, Piper Sandler downgraded Endo (ENDP), noting the generic competition to the vasopressin injection, which added $155.9M to the company topline in 1Q 2022 with ~30% YoY decline.
Seeking Alpha • Jul 12

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International (NASDAQ:ENDP) shares plunged ~20% Tuesday after The Wall Street Journal reported that the generic drugmaker is advancing towards a bankruptcy filing without reaching a settlement on opioid claims against the company. According to people familiar with the matter, despite years of negotiations with opioid claimants, Endo (ENDP) is weighing chapter 11 bankruptcy to restructure its over $8B debt and thousands of ongoing litigations. Endo (ENDP) has been negotiating with a group of senior creditors after the company missed interest payments to junior bondholders last month, the people said, adding that the management expects to reach a deal with them before a near-term bankruptcy process starts. However, a bankruptcy filing is unlikely if the company inks agreements with junior bondholders and opioid plaintiffs, the people said, noting that the situation could change. Endo (ENDP) declined to comment. Read: “Bankruptcy filing should be imminent” for Endo (ENDP), Seeking Alpha contributor CashFlow Hunter predicted in May.
Seeking Alpha • Jun 29

Endo International cools off, giving back some of its 85% Tuesday gain

Shares of Endo International are down 24% in Wednesday afternoon trading, a day after the pharma closed up 85%. The reason for Tuesday's surge was a news release issued by law firm White & Case on behalf of a group of institutional investors holding unsecured notes in Endo (NASDAQ:ENDP) subsidiaries. The group has proposed that the company commence a cash tender offer or commence a debt-for-debt exchange. Also, it is against a near-term bankruptcy filing as Endo (ENDP) has strong liquidity and it "could destroy significant value for stakeholders." Endo (ENDP) has been struggling as a result of multi-million-dollar settlements in state opioid crisis cases.
Seeking Alpha • May 10

Endo: Stick A Fork In It

Second quarter guidance implies catastrophic sales and margins from Vasostrict. Bonds plummeted implying first lien debt might be impaired. Possibly impairment of first lien debt and near certain impairment of second lien debt means zero equity value. Bankruptcy filing should be imminent.
Seeking Alpha • Mar 07

Endo: About As Bad As It Gets

Entrance of generic competitor to Vasostrict materially hurting revenue. QWO uptake seems slow with concerns around discoloration side-effect. Q1 guide implies leverage rising dangerous levels. Bankruptcy seems like an increasingly likely option.
Seeking Alpha • Dec 16

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo several months ago. Vasostrict is Endo's biggest revenue source, responsible for $786 million of high margin sales last year. Eagle expects 180-day marketing exclusivity for vasopressin. Continue to see the stock as high risk.
Seeking Alpha • Nov 02

Endo: A Win In California But Equity Value Still A Question

California State Court hands Endo and other opioid producers a temporary win in liability trial. Tentative ruling directs manufacturers to file a statement of decision within 30 days. Ruling likely takes away major liability in the country's biggest state at least for a while. Leverage remains too high, particularly with Vasostrict EBITDA at risk. Bankruptcy is now likely off the table but struggle to see equity value.
Seeking Alpha • Aug 31

Endo International: Loses Vasostrict Trial

Judge rules Eagle Pharmaceuticals' version of the drug does not infringe on two patents held by Par Pharmaceuticals, the unit that produces vasostrict. Expect Eagle to start producing and marketing a generic form of vasostrict to treat low blood pressure in the next few months. Approximately 30% of Endo Pharmaceuticals' revenue and EBITDA will take a hit. The loss likely wipes out any equity value for Endo and impairs unsecured bonds.
Seeking Alpha • Aug 20

Endo International: Hires Restructuring Advisor

The company is hiring Alvarez & Marsal, which specializes in bankruptcy restructuring. The move is somewhat surprising from a timing perspective. New York opioid and Vasostrict trials are still ongoing.
Seeking Alpha • Aug 07

Endo International: All About Ongoing Litigation

Company settled with the eastern TN counties for $35mm but do the economics make any sense? NY litigation is ongoing with plaintiffs seeking default liability judgment on the same grounds as TN. Vasostrict trial with Eagle Pharmaceuticals is ongoing. >25% of EBITDA at risk. Quarter operationally solid, but questions remain on market acceptance of QWO.
Seeking Alpha • Jul 15

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

The denied request is likely the last chance to stop the Tennessee damages trial set to begin on July 26. The company already has a default judgment against it. The company could face a $2.4 billion judgment leveled against it. Appeal denial is one more piece pointing to likely bankruptcy filing.
Seeking Alpha • Jun 30

Endo International: Bankruptcy Seems Like The Only Practical Option

A Tennessee state court issued a "default judgement" in April against the company in the lawsuit by county prosecutors over the company's generic for oxycontin, Opana. Earlier this month, a Tennessee appellate court declined to review that default judgement. The damages trial begins on July 26 in Tennessee. Plaintiffs are seeking $2.4 billion. A trial for a suit against the company begins in New York on June 28th and a California trial is ongoing. A bankruptcy filing is very likely the only way to settle all of these cases in a manner that preserves value.

Rendimenti per gli azionisti

ENDP.QUS PharmaceuticalsUS Mercato
7D0%1.9%-0.8%
1Y-98.9%41.8%27.1%

Ritorno vs Industria: ENDP.Q ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 41.8 % nell'ultimo anno.

Rendimento vs Mercato: ENDP.Q ha avuto una performance inferiore al mercato US che ha registrato un rendimento 27.1 % nell'ultimo anno.

Volatilità dei prezzi

Is ENDP.Q's price volatile compared to industry and market?
ENDP.Q volatility
ENDP.Q Average Weekly Movement207.3%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di ENDP.Q è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale di ENDP.Q è aumentata da 125% a 207% nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
19972,931Blaise Colemanwww.endo.com

Endo International plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Endo International con la sua capitalizzazione di mercato?
ENDP.Q statistiche fondamentali
Capitalizzazione di mercatoUS$141.13k
Utili (TTM)-US$2.45b
Ricavi(TTM)US$2.01b
0.0x
Rapporto P/S
0.0x
Rapporto P/E

ENDP.Q è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ENDP.Q Conto economico (TTM)
RicaviUS$2.01b
Costo del fatturatoUS$941.90m
Profitto lordoUS$1.07b
Altre speseUS$3.52b
Utili-US$2.45b

Ultimi utili riportati

Dec 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)-10.41
Margine lordo53.17%
Margine di profitto netto-121.69%
Rapporto debito/patrimonio netto-123.5%

Come si è comportato ENDP.Q nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/05/02 03:36
Prezzo dell'azione a fine giornata2024/05/02 00:00
Utili2023/12/31
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Endo, Inc. è coperta da 32 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research